Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · Real-Time Price · USD
1.780
+0.030 (1.71%)
At close: May 23, 2025, 4:00 PM
1.770
-0.010 (-0.55%)
After-hours: May 23, 2025, 7:58 PM EDT
1.71%
Market Cap 594.40M
Revenue (ttm) 212.68M
Net Income (ttm) -375.36M
Shares Out 333.93M
EPS (ttm) -1.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,861,848
Open 1.700
Previous Close 1.750
Day's Range 1.670 - 1.790
52-Week Range 1.639 - 12.505
Beta 1.06
Analysts Buy
Price Target 12.22 (+586.52%)
Earnings Date May 8, 2025

About IOVA

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 838
Stock Exchange NASDAQ
Ticker Symbol IOVA
Full Company Profile

Financial Performance

In 2024, Iovance Biotherapeutics's revenue was $164.07 million, an increase of 13698.99% compared to the previous year's $1.19 million. Losses were -$372.18 million, -16.18% less than in 2023.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price forecast is $12.22, which is an increase of 586.52% from the latest price.

Price Target
$12.22
(586.52% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IOVA FRAUD NEWS: Iovance Biotherapeutics, Inc. is Being Sued for Securities Fraud; Investors That Lost Money Are Urged to Contact BFA Law by July 14 Court Deadline

NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ...

23 hours ago - Accesswire

Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class ...

1 day ago - GlobeNewsWire

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previousl...

1 day ago - GlobeNewsWire

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).

3 days ago - GlobeNewsWire

Scott+Scott Attorneys at Law LLP Alerts Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class ...

3 days ago - GlobeNewsWire

IOVA LAWSUIT: Lose Money on Iovance Biotherapeutics, Inc.? Contact BFA Law before July 14 Court Deadline

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certa...

3 days ago - GlobeNewsWire

Iovance Shareholders Should Contact Shareholder Rights Firm Regarding Potential Legal Claims

NEW YORK , May 17, 2025 /PRNewswire/ -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating potential claims against Iovance  Biotherapeutics, Inc. (Nasdaq: IOVA) and its execut...

7 days ago - PRNewsWire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliverin...

7 days ago - GlobeNewsWire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company...

8 days ago - Accesswire

Lovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman

IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / May 15, 2025 / In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), investors watche...

9 days ago - Accesswire

Iovance Biotherapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - IOVA

LOS ANGELES--(BUSINESS WIRE)--Iovance Biotherapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - IOVA.

9 days ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Iovance Biotherapeutics, Inc. (IOVA) And Encourages Stockholders to Connect

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company...

9 days ago - Accesswire

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% – Hagens Berman

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the ...

9 days ago - GlobeNewsWire

Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company...

10 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Iovance Biotherapeutics, Inc. (IOVA) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company...

11 days ago - Accesswire

Iovance Biotherapeutics' (IOVA) Annual Maintenance: Assurances Collide with Adverse Disclosure as Shares Plunge 44% - Hagens Berman

IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , May 13, 2025 /PRNewswire/ -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the c...

11 days ago - PRNewsWire

Bronstein, Gewirtz & Grossman, LLC Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors to Inquire about Securities Investigation

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Iovance Biotherapeutics, Inc. ("Iovance" or "the Company...

11 days ago - Accesswire

Iovance Biotherapeutics: Abysmal Q1 2025 Performance Creates Buying Opportunity

Iovance Biotherapeutics' stock plummeted 45% after a Q1 earnings miss, driven by temporary manufacturing issues and reduced revenue guidance. Management expects a rebound in Q2 with resumed full manuf...

12 days ago - Seeking Alpha

Iovance Stock Sinks 46%. Here's Why the Biotech Is Tumbling.

The oncology drug maker posts a wider-than-expected loss in the first quarter.

15 days ago - Barrons

No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed

IOVA's Q1'25 product revenue was $49.3M, impacted by production facility maintenance; however, Q2'25 estimates for infusions imply weak growth, despite not being impacted by production. Replimune's RP...

15 days ago - Seeking Alpha

Iovance Biotherapeutics, Inc. (IOVA) Q1 2025 Earnings Call Transcript

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Sara Pellegrino - SVP, IR and Corporate Communications Fred Vogt - Interim CEO...

15 days ago - Seeking Alpha

Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infi...

21 days ago - GlobeNewsWire

Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in...

4 weeks ago - GlobeNewsWire

Top 3 Health Care Stocks That Are Set To Fly This Month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: ARVNSLP
2 months ago - Benzinga

Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)

Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showe...

3 months ago - Seeking Alpha